Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 6:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 50,299 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cancer Malignancies Clear all
Terminated Phase 1 Interventional

The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer

NCT03162562
View directory record Official record
Conditions
Cancer of Ovary, Neoplasms, Ovarian, Ovarian Cancer Stage IV, Ovarian Cancer Recurrent, Ovarian Cancer Stage III, Ovary Cancer
Interventions
Oregovomab, Poly ICLC
Biological · Drug
Lead sponsor
CanariaBio Inc.
Industry
Eligibility
18 Years to 90 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Orlando, Florida • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Oct 20, 2026, 6:53 PM EDT
Terminated Not applicable Interventional

Identification and Prevention of Pelvic Floor Dysfunction in Gynecologic Cancer Survivors

NCT05769062
View directory record Official record
Conditions
Gynecologic Cancer
Interventions
Single digit pelvic exam
Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 20, 2026, 6:53 PM EDT
Suspended Phase 2 Interventional

Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma

NCT06014827
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Osimertinib, Positron Emission Tomography, Stereotactic Body Radiation Therapy, Survey Administration
Procedure · Drug · Radiation + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Duarte, California • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 20, 2026, 6:53 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia

NCT00233454
View directory record Official record
Conditions
Systemic Mastocytosis, Aggressive (ASM), Leukemia, Mast Cell, Hematological Non-mast Cell Lineage Disease (AHNMD)
Interventions
Midostaurin
Drug
Lead sponsor
Jason Robert Gotlib
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
3
States / cities
Stanford, California • Boston, Massachusetts • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 20, 2018 · Synced Oct 20, 2026, 6:53 PM EDT
Completed Phase 2 Interventional Results available

Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM)

NCT04682405
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Uproleselan, Placebo, Melphalan
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 15, 2023 · Synced Oct 20, 2026, 6:53 PM EDT
Terminated Phase 4 Interventional Results available

Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab.

NCT04381494
View directory record Official record
Conditions
Unresectable Stage III NSCLC
Interventions
Multiparametric Mobile Technology
Device
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
18
States / cities
Long Beach, California • Santa Ana, California • Englewood, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 20, 2026, 6:53 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma

NCT05409066
View directory record Official record
Conditions
Follicular Lymphoma (FL)
Interventions
Epcoritamab, Rituximab, Lenalidomide
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
31
States / cities
Tucson, Arizona • Little Rock, Arkansas • Berkeley, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 20, 2026, 6:53 PM EDT
Terminated Early Phase 1 Interventional

Impact of Ribociclib on Head and Neck Squamous Cell Cancer

NCT03179956
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Ribociclib
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Oct 20, 2026, 6:53 PM EDT
Terminated Phase 2 Interventional Results available

Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer

NCT02978222
View directory record Official record
Conditions
Platinum Sensitive Ovarian Cancer, Ovarian Cancer
Interventions
FRα peptide plus Adjuvant (GM-CSF), Adjuvant (GM-CSF) Alone
Biological · Drug
Lead sponsor
Marker Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
18
States / cities
Birmingham, Alabama • Phoenix, Arizona • Newport Beach, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2022 · Synced Oct 20, 2026, 6:53 PM EDT
Terminated Not applicable Interventional Results available

Endoscopic Ultrasound (EUS) Guided Fine Needle Aspiration (FNA) EUS-FNA of Solid Pancreatic Mass Lesions Using a Novel Corkscrew Technique: a Pilot Study

NCT02116322
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
EUS-FNA with Corkscrew technique, Expect 19 G Flex needle
Procedure · Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 90 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Oct 20, 2026, 6:53 PM EDT
Terminated Phase 2 Interventional Results available

Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer

NCT00609622
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
sunitinib, mFOLFOX6, bevacizumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
81
States / cities
Fairhope, Alabama • Mobile, Alabama • Chandler, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2012 · Synced Oct 20, 2026, 6:53 PM EDT
Completed Phase 2 Interventional

Frameless Fractionated Stereotactic Radiation in Treating Patients With Brain Metastases

NCT02798029
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Brain
Interventions
Frameless Fractionated Stereotactic Radiation Therapy
Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
4
States / cities
Albuquerque, New Mexico • Conroe, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Oct 20, 2026, 6:53 PM EDT
Completed Phase 1Phase 2 Interventional

Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma

NCT01719302
View directory record Official record
Conditions
Stage III Adult Soft Tissue Sarcoma
Interventions
Gemcitabine, Docetaxel, Pazopanib
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Oct 20, 2026, 6:53 PM EDT
Completed Not applicable Interventional

Continuous Quality Improvement (CQI) Pilot Study Evaluating the Utility of an Educational Video

NCT02062853
View directory record Official record
Conditions
Actinic Keratoses
Interventions
Video Group, Verbal Group
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 19, 2017 · Synced Oct 20, 2026, 6:53 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Ovarian Ultrasonography for the Clinical Evaluation of Polycystic Ovary Syndrome

NCT03547453
View directory record Official record
Conditions
Polycystic Ovary Syndrome (PCOS), Menstrual Irregularity, Overweight and Obesity
Interventions
Not listed
Lead sponsor
Cornell University
Other
Eligibility
18 Years and older · Female only
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Oct 20, 2026, 6:53 PM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma

NCT01696045
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Ipilimumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years to 17 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
14
States / cities
Phoenix, Arizona • Los Angeles, California • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2017 · Synced Oct 20, 2026, 6:53 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase

NCT02369653
View directory record Official record
Conditions
Lymphoma, Acute Lymphoblastic Leukemia
Interventions
Apixaban, No systemic anticoagulant prophylaxis
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
1 Year to 17 Years
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
64
States / cities
Phoenix, Arizona • Duarte, California • Loma Linda, California + 56 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Oct 20, 2026, 6:53 PM EDT
Completed Phase 3 Interventional

Carboplatin With or Without Gemcitabine in Treating Patients With Advanced Ovarian Epithelial Cancer That Has Not Responded to Previous Chemotherapy

NCT00006453
View directory record Official record
Conditions
Ovarian Cancer
Interventions
carboplatin, gemcitabine hydrochloride
Drug
Lead sponsor
AGO Study Group
Other
Eligibility
18 Years to 120 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
1
States / cities
Duluth, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 23, 2015 · Synced Oct 20, 2026, 6:53 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Implement and Test Visual Consent Template and Process

NCT06804837
View directory record Official record
Conditions
Cancer, Alzheimer Disease
Interventions
Visual consent, Standard consent
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
266 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
St Louis, Missouri • Chapel Hill, North Carolina • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 20, 2026, 6:53 PM EDT
Terminated Not applicable Interventional

A Pilot Trial of Interpersonal Psychotherapy for the Treatment of Depression in Patients With Prostate, Colorectal, Lung and Pancreatic Cancer

NCT01940237
View directory record Official record
Conditions
Depression, Pancreatic Cancer, Lung Cancer, Colon Cancer, Prostate Cancer
Interventions
Psychotherapy
Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 19, 2017 · Synced Oct 20, 2026, 6:53 PM EDT
Completed Phase 2 Interventional

Paclitaxel Plus Monoclonal Antibody Therapy in Treating Women With Recurrent or Metastatic Breast Cancer

NCT00003539
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, paclitaxel
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 20, 2026, 6:53 PM EDT
Completed Phase 2 Interventional Results available

Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma

NCT03304639
View directory record Official record
Conditions
Advanced Merkel Cell Carcinoma, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8, Metastatic Merkel Cell Carcinoma, Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIA Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIB Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
Interventions
Pembrolizumab, Stereotactic Body Radiation Therapy
Biological · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
254
States / cities
Anchorage, Alaska • Tucson, Arizona • Fort Smith, Arkansas + 172 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 20, 2026, 6:53 PM EDT
Terminated Phase 2 Interventional Results available

Bevacizumab With or Without Docetaxel in Treating Patients With Previously Treated Metastatic Pancreatic Cancer

NCT00066677
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
rhuMAB-VEGF, docetaxel
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Oct 20, 2026, 6:53 PM EDT
Completed Not applicable Interventional

Patient Reported Outcomes and Patient Education in Cellular Therapy Patients

NCT04853277
View directory record Official record
Conditions
Stem Cell Transplant, CAR T-Cell Transplant, CAR T-Cell Therapy, Cellular Therapy, Hematopoietic Stem Cell Transplant, HSCT, Multiple Myeloma, Leukemia, Lymphoma
Interventions
Education
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Oct 20, 2026, 6:53 PM EDT